Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study.

Ghobrial IM, Fonseca R, Greipp PR, Blood E, Rue M, Vesole DH, Gertz MA; Eastern Cooperative Oncology Group..

Cancer. 2004 Dec 1;101(11):2593-8.

2.

CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.

Treon SP, Agus TB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanouilides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson KC, Byrd JC.

J Immunother. 2001 May-Jun;24(3):272-9.

PMID:
11394506
3.

[Effective treatment with rituximab in two patients with Waldenström macroglobulinemia].

Yoshimi A, Arai S, Iijima K, Iki S, Usuki K, Urabe A.

Rinsho Ketsueki. 2005 Oct;46(10):1109-13. Japanese.

PMID:
16440772
4.

Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.

Ciccarelli BT, Yang G, Hatjiharissi E, Ioakimidis L, Patterson CJ, Manning RJ, Xu L, Liu X, Tseng H, Gong P, Sun J, Zhou Y, Treon SP.

Clin Lymphoma Myeloma. 2009 Mar;9(1):56-8. doi: 10.3816/CLM.2009.n.014.

PMID:
19362974
5.

Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98).

Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, Greipp PR.

Leuk Lymphoma. 2004 Oct;45(10):2047-55.

PMID:
15370249
6.

Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.

Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, Frankel SR, Touroutoglou N, Turnbull B, Anderson KC, Maloney DG, Fox EA.

J Clin Oncol. 2005 Jan 20;23(3):474-81.

PMID:
15659493
7.

Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial.

Gertz MA, Abonour R, Heffner LT, Greipp PR, Uno H, Rajkumar SV.

Br J Haematol. 2009 Dec;147(5):677-80. doi: 10.1111/j.1365-2141.2009.07892.x. Epub 2009 Sep 14.

8.

Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide.

Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Zervas K, Tsatalas C, Kokkinis G, Repoussis P, Symeonidis A, Delimpasi S, Katodritou E, Vervessou E, Michali E, Pouli A, Gika D, Vassou A, Terpos E, Anagnostopoulos N, Economopoulos T, Pangalis G.

J Clin Oncol. 2007 Aug 1;25(22):3344-9. Epub 2007 Jun 18.

PMID:
17577016
9.

Immunoglobulin M 'Flare' after rituximab-associated acute tubular necrosis in Waldenström's macroglobulinemia.

Izzedine H, Bourry E, Amrouche L, Brocheriou I, Uzunov M, Capron F, Leblond V, Deray G.

Int J Hematol. 2009 Mar;89(2):218-22. doi: 10.1007/s12185-008-0244-7. Epub 2009 Jan 21.

PMID:
19156501
10.

Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.

Treon SP, Soumerai JD, Branagan AR, Hunter ZR, Patterson CJ, Ioakimidis L, Chu L, Musto P, Baron AD, Nunnink JC, Kash JJ, Terjanian TO, Hyman PM, Nawfel EL, Sharon DJ, Munshi NC, Anderson KC.

Clin Cancer Res. 2009 Jan 1;15(1):355-60. doi: 10.1158/1078-0432.CCR-08-0862.

11.

Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.

Treon SP, Branagan AR, Hunter Z, Santos D, Tournhilac O, Anderson KC.

Ann Oncol. 2004 Oct;15(10):1481-3.

PMID:
15367407
12.

Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).

Dimopoulos MA, García-Sanz R, Gavriatopoulou M, Morel P, Kyrtsonis MC, Michalis E, Kartasis Z, Leleu X, Palladini G, Tedeschi A, Gika D, Merlini G, Kastritis E, Sonneveld P.

Blood. 2013 Nov 7;122(19):3276-82. doi: 10.1182/blood-2013-05-503862. Epub 2013 Sep 4.

13.

Waldenström macroglobulinemia.

Vijay A, Gertz MA.

Blood. 2007 Jun 15;109(12):5096-103. Epub 2007 Feb 15. Review.

14.

Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression.

Dimopoulos MA, Alexanian R, Gika D, Anagnostopoulos A, Zervas C, Zomas A, Kyrtsonis MC, Anagnostopoulos N, Pangalis GA, Weber DM.

Leuk Lymphoma. 2004 Oct;45(10):2057-61.

PMID:
15370250
15.

Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: results and cost analysis.

Annibali O, Petrucci MT, Martini V, Tirindelli MC, Levi A, Fossati C, Del Bianco P, Mandelli F, Foa R, Avvisati G.

Cancer. 2005 Feb 1;103(3):582-7.

16.

Rituximab therapy in monoclonal IgM-related neuropathies.

Kilidireas C, Anagnostopoulos A, Karandreas N, Mouselimi L, Dimopoulos MA.

Leuk Lymphoma. 2006 May;47(5):859-64.

PMID:
16753870
17.

[Treatment of Waldenström macroglobulinaemia--the experience of one centre].

Adam Z, Pour L, Krejcí M, Korístek Z, Navrátil M, Krivanová A, Zahradová L, Hájek R.

Vnitr Lek. 2009 Jan;55(1):9-17. Czech.

PMID:
19227950
18.

Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen.

Treon SP, Hanzis C, Manning RJ, Ioakimidis L, Patterson CJ, Hunter ZR, Sheehy P, Turnbull B.

Br J Haematol. 2011 Aug;154(3):357-62. doi: 10.1111/j.1365-2141.2011.08750.x. Epub 2011 May 25.

PMID:
21615385
19.

Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).

Dhodapkar MV, Jacobson JL, Gertz MA, Rivkin SE, Roodman GD, Tuscano JM, Shurafa M, Kyle RA, Crowley JJ, Barlogie B.

Blood. 2001 Jul 1;98(1):41-8.

20.

Extended rituximab therapy in Waldenström's macroglobulinemia.

Treon SP, Emmanouilides C, Kimby E, Kelliher A, Preffer F, Branagan AR, Anderson KC, Frankel SR; Waldenström's Macroglobulinemia Clinical Trials Group..

Ann Oncol. 2005 Jan;16(1):132-8.

PMID:
15598950

Supplemental Content

Support Center